# NCT03456076 (NCT03456076)

> A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03456076
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Hoffmann-La Roche
- Conditions: Carcinoma, Non-Small-Cell Lung
- Interventions: Alectnib; Cisplatin; Vinorelbine; Gemcitabine; Pemetrexed; Carboplatin
- Enrollment: 257
- Primary outcome: Disease-free Survival (DFS), as Assessed by the Investigator

## Commentary we found

- X threads: 5

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct03456076